GOSS
Price
$2.43
Change
-$0.07 (-2.80%)
Updated
Oct 8, 04:59 PM (EDT)
Capitalization
572.2M
29 days until earnings call
NXTC
Price
$6.85
Change
+$0.72 (+11.75%)
Updated
Oct 8, 04:53 PM (EDT)
Capitalization
16.4M
22 days until earnings call
Interact to see
Advertisement

GOSS vs NXTC

Header iconGOSS vs NXTC Comparison
Open Charts GOSS vs NXTCBanner chart's image
Gossamer Bio
Price$2.43
Change-$0.07 (-2.80%)
Volume$175.67K
Capitalization572.2M
NextCure
Price$6.85
Change+$0.72 (+11.75%)
Volume$447
Capitalization16.4M
GOSS vs NXTC Comparison Chart in %
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GOSS vs. NXTC commentary
Oct 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and NXTC is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 08, 2025
Stock price -- (GOSS: $2.50 vs. NXTC: $6.13)
Brand notoriety: GOSS and NXTC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 66% vs. NXTC: 26%
Market capitalization -- GOSS: $572.2M vs. NXTC: $16.4M
GOSS [@Biotechnology] is valued at $572.2M. NXTC’s [@Biotechnology] market capitalization is $16.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileNXTC’s FA Score has 1 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • NXTC’s FA Score: 1 green, 4 red.
According to our system of comparison, both GOSS and NXTC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 4 TA indicator(s) are bullish while NXTC’s TA Score has 6 bullish TA indicator(s).

  • GOSS’s TA Score: 4 bullish, 5 bearish.
  • NXTC’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NXTC is a better buy in the short-term than GOSS.

Price Growth

GOSS (@Biotechnology) experienced а -4.94% price change this week, while NXTC (@Biotechnology) price change was +4.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.11%. For the same industry, the average monthly price growth was +19.03%, and the average quarterly price growth was +87.04%.

Reported Earning Dates

GOSS is expected to report earnings on Nov 06, 2025.

NXTC is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+9.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GOSS($572M) has a higher market cap than NXTC($16.4M). GOSS YTD gains are higher at: 176.365 vs. NXTC (-33.773). NXTC has higher annual earnings (EBITDA): -61.2M vs. GOSS (-128.6M). GOSS has more cash in the bank: 213M vs. NXTC (35.3M). NXTC has less debt than GOSS: NXTC (4.67M) vs GOSS (203M). GOSS has higher revenues than NXTC: GOSS (40.2M) vs NXTC (0).
GOSSNXTCGOSS / NXTC
Capitalization572M16.4M3,488%
EBITDA-128.6M-61.2M210%
Gain YTD176.365-33.773-522%
P/E RatioN/AN/A-
Revenue40.2M0-
Total Cash213M35.3M603%
Total Debt203M4.67M4,351%
FUNDAMENTALS RATINGS
GOSS vs NXTC: Fundamental Ratings
GOSS
NXTC
OUTLOOK RATING
1..100
6627
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3744
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NXTC's Valuation (12) in the Biotechnology industry is somewhat better than the same rating for GOSS (47) in the Pharmaceuticals Major industry. This means that NXTC’s stock grew somewhat faster than GOSS’s over the last 12 months.

NXTC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that NXTC’s stock grew similarly to GOSS’s over the last 12 months.

NXTC's SMR Rating (100) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that NXTC’s stock grew similarly to GOSS’s over the last 12 months.

GOSS's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as NXTC (44) in the Biotechnology industry. This means that GOSS’s stock grew similarly to NXTC’s over the last 12 months.

GOSS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as NXTC (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to NXTC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GOSSNXTC
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 28 days ago
84%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 16 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SEGG4.040.03
+0.75%
Lottery. com Inc
NTR60.640.27
+0.45%
Nutrien Ltd
CTLP10.620.02
+0.19%
Cantaloupe
CARG35.50-0.74
-2.04%
CarGurus
FORR8.54-0.52
-5.74%
Forrester Research